OctoPlus N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
11 jul 2010 - 23:09
Statutaire naam
OctoPlus N.V.
Titel
OctoPlus signs drug development contract with The Medicines Company
Bericht
OctoPlus N.V. (“OctoPlus” or the “Company”) (Euronext: OCTO), announces today that it has signed a pharmaceutical development and manufacturing contract with a new client, US-based The Medicines Company. The undisclosed contract value will make a material contribution to OctoPlus’ annual revenues.
Under the contract terms, OctoPlus will perform process development and clinical manufacturing for The Medicines Company related to MDCO-216 (ApoA-I Milano/phospholipid complex).
Datum laatste update: 28 juli 2024